Surfactant Protein D Levels in GCF Before and After MINST in Periodontitis
Evaluation of Surfactant Protein D (SP-D) Levels in the GCF of Periodontitis Patients Associated With the Endpoints After Minimally Invasive Non-surgical Periodontal Therapy: A Before and After Study
This study will evaluate changes in Surfactant Protein D (SP-D) levels in gingival crevicular fluid (GCF) of patients with periodontitis before and after minimally invasive non-surgical periodontal therapy (MINST).
Participants diagnosed with stage II or III periodontitis will receive minimally invasive non-surgical periodontal treatment. GCF samples will be collected at baseline and 6 months after treatment, and SP-D levels will be measured using enzyme-linked immunosorbent assay (ELISA).
The study will also assess clinical periodontal outcomes, including full-mouth plaque score, full-mouth bleeding score, probing pocket depth, clinical attachment level, gingival recession, and patient satisfaction. Each participant will serve as their own control by comparing baseline values with 6-month post-treatment values.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Periodontitis is a chronic multifactorial inflammatory disease characterized by progressive destruction of the supporting periodontal tissues. Conventional clinical parameters, such as probing pocket depth, bleeding on probing, and clinical attachment level, are useful for diagnosis and follow-up but may reflect tissue destruction after it has already occurred. Therefore, biomarkers that reflect the biological inflammatory status of periodontal tissues may improve monitoring of disease activity and treatment response.
Surfactant Protein D (SP-D) is an innate immune molecule involved in host defense and modulation of inflammation. It has been detected in oral fluids, including gingival crevicular fluid, and may be associated with periodontal inflammation. This study aims to evaluate whether SP-D levels in GCF change after minimally invasive non-surgical periodontal therapy in patients with periodontitis.
This is a single-group before-and-after interventional clinical study. Eligible participants with stage II or III periodontitis will be recruited from the outpatient periodontal clinics of the Faculty of Dentistry, Cairo University. At baseline, periodontal clinical parameters will be recorded, including full-mouth plaque score, full-mouth bleeding score, probing pocket depth, clinical attachment level, and gingival recession. GCF samples will be collected from selected periodontal sites using sterile paper strips and stored until biochemical analysis.
All participants will receive minimally invasive non-surgical periodontal therapy, including oral hygiene instructions, supragingival plaque control, and subgingival instrumentation using minimally invasive techniques. Treatment will be performed using fine periodontal instruments, thin ultrasonic tips, magnification when available, and local anesthesia when needed to improve patient comfort and minimize tissue trauma.
After 6 months, participants will be recalled for clinical re-evaluation and collection of post-treatment GCF samples from the same sites. SP-D levels will be measured using ELISA. The primary outcome will be the change in SP-D level from baseline to 6 months after treatment. Secondary outcomes will include changes in plaque score, bleeding score, probing pocket depth, clinical attachment level, gingival recession, and patient satisfaction.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Hossam Ashraf ElMasry
- Numero di telefono: +201129559757
- Email: hossam.eldamarany@dentistry.cu.edu.eg
Luoghi di studio
-
-
-
Cairo, Egitto, 12613
- Reclutamento
- Faculty of Dentistry, Cairo University
-
Contatto:
- Faculty of Dentistry, Cairo University
- Numero di telefono: 01002159535
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Male and female participants aged 18 years or older.
- Diagnosis of periodontitis, classified as stage II or stage III according to the 2018 classification system.
- Presence of at least one tooth with probing pocket depth (PPD) of 5 mm or more, clinical attachment loss (CAL), and radiographic evidence of bone loss.
- Presence of at least one intrabony defect with a radiographic intrabony component measuring 3 mm or more.
Exclusion Criteria:
- Current smokers or individuals with a history of smoking within the past year.
- Pregnant or lactating women.
- Use of systemic antibiotics or anti-inflammatory medications within the last 3 months.
- Known allergy to any materials or agents used during periodontal therapy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: MINST Group
Participants diagnosed with periodontitis will receive minimally invasive non-surgical periodontal therapy (MINST).
Clinical periodontal parameters and gingival crevicular fluid samples will be collected at baseline and 6 months after treatment to assess changes in SP-D levels and periodontal outcomes.
|
Minimally invasive non-surgical periodontal therapy will include oral hygiene instructions, supragingival plaque control, and subgingival instrumentation using fine periodontal instruments, miniature Gracey curettes, thin ultrasonic tips, magnification when available, and local anesthesia when needed.
Debridement will be performed for periodontal pockets while minimizing trauma to the soft tissues.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Surfactant Protein D (SP-D) Levels in Gingival Crevicular Fluid
Lasso di tempo: Baseline and 6 months after treatment
|
Change in Surfactant Protein D (SP-D) concentration in gingival crevicular fluid from baseline to 6 months after minimally invasive non-surgical periodontal therapy.
SP-D levels will be measured using enzyme-linked immunosorbent assay (ELISA) and reported in ng/mL.
|
Baseline and 6 months after treatment
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Full-Mouth Plaque Score
Lasso di tempo: Baseline and 6 months after treatment
|
Change in full-mouth plaque score from baseline to 6 months after treatment.
Plaque score will be recorded as the percentage of sites with visible plaque.
|
Baseline and 6 months after treatment
|
|
Change in Probing Pocket Depth
Lasso di tempo: Baseline and 6 months after treatment
|
Change in probing pocket depth from baseline to 6 months after treatment.
Probing pocket depth will be measured in millimeters using a UNC-15 periodontal probe.
|
Baseline and 6 months after treatment
|
|
Change in Clinical Attachment Level
Lasso di tempo: Baseline and 6 months after treatment
|
Change in clinical attachment level from baseline to 6 months after treatment.
Clinical attachment level will be measured in millimeters using a UNC-15 periodontal probe.
|
Baseline and 6 months after treatment
|
|
Change in Gingival Recession
Lasso di tempo: Baseline and 6 months after treatment
|
Change in gingival recession from baseline to 6 months after treatment.
Gingival recession will be measured in millimeters from the cemento-enamel junction to the gingival margin using a UNC-15 periodontal probe.
|
Baseline and 6 months after treatment
|
|
Patient Satisfaction Score
Lasso di tempo: 6 months after treatment
|
Patient satisfaction will be assessed at the 6-month follow-up using a standardized 5-point Likert-scale questionnaire.
Higher scores indicate greater patient satisfaction.
|
6 months after treatment
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PER 7-2-1
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .